New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
12:18 EDTGILDGilead announces 24-week Phase 2 results for once-daily HIV regimen
Gilead Sciences announced detailed 24-week results from a Phase 2 study evaluating a once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented today in a latebreaker session at the 20th Conference on Retroviruses and Opportunistic Infections taking place in Atlanta. In Study 102, HIV-positive treatment-na´ve adult patients were randomized to receive the investigational TAF-based regimen or Stribild. At 24 weeks, 87% of patients taking TAF and 90% of patients taking Stribild achieved HIV RNA less than 50 copies/mL, based on the FDA snapshot algorithm. There were no statistically significant differences in the frequency and nature of Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse events were similar between the two arms. Both regimens were generally well tolerated.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:00 EDTGILDOptions Update; May 29, 2015
Subscribe for More Information
May 28, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:35 EDTGILDGilead: MAA for fixed-dose Emtricitabine, Tenofovir Alafenamide validated by EMA
Subscribe for More Information
May 27, 2015
16:51 EDTGILDGilead inaugurates new lab and $100M investment
Gilead Sciences' wholly-owned subsidiary Gilead Alberta ULC opened the first of two new laboratory buildings at its Edmonton campus, and announced an additional $100M investment to further expand and upgrade the site as the biopharmaceutical company broadens its pipeline of treatments in areas of unmet medical need. A second laboratory building is under construction and set for completion in the spring of 2016.
13:45 EDTGILDGilead HBV future likely from assets other than GS-4774, says Deutsche Bank
Subscribe for More Information
May 26, 2015
10:46 EDTGILDAnthem sued for denying coverage for Gilead's Harvoni, WSJ says
Subscribe for More Information
May 22, 2015
16:00 EDTGILDOptions Update; May 22, 2015
Subscribe for More Information
May 21, 2015
10:58 EDTGILDDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 20, 2015
09:07 EDTGILDGilead's patent for Hep C drug sofosbuvir challenged by NGO's in five countries
Subscribe for More Information
May 19, 2015
10:09 EDTGILDGilead CFO says 'really excited' about options to grow beyond 2018
Subscribe for More Information
07:56 EDTGILDGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:28 EDTGILDUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 18, 2015
19:43 EDTGILDAnthem Blue Cross sued for limiting Harvoni usage, LA Times says
Subscribe for More Information
16:16 EDTGILDGilead confirms plans to present tomorrow at UBS conference, Feuerstein reports
Subscribe for More Information
14:42 EDTGILDAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use